API Family
Mycophenolate Mofetil
Storage Condition
Refer MSDS for complete information
Synonyms
Mycophenolic Acid O-Methyl Impurity
Application Notes
Useful research chemical for a range of applications
Hazard Compound
Refer MSDS for complete information
O-Methyl Mycophenolic Acid is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
O-Methyl Mycophenolic Acid usage and description
O-Methyl Mycophenolic Acid (MMP) is a derivative of Mycophenolic Acid (MPA) that is used in immunosuppressive therapy. It is a prodrug that is metabolized in the body to form MPA, which inhibits the activity of inosine monophosphate dehydrogenase (IMPDH) and, therefore, suppresses the proliferation of T and B cells.
MMP is commonly used as an alternative to MPA in patients who experience gastrointestinal side effects from MPA. It is also used in combination with other immunosuppressive drugs to prevent organ rejection in transplant patients.
The chemical structure of MMP is similar to MPA, with a methyl group attached to the nitrogen of the acyl side chain. This modification increases the lipophilicity of the molecule, which enhances its bioavailability and allows for more efficient absorption in the gastrointestinal tract.
MMP is primarily metabolized by UDP-glucuronosyltransferases (UGTs) in the liver and excreted in the urine as glucuronide conjugates. The pharmacokinetics of MMP are similar to those of MPA, with a half-life of approximately 17 hours and a steady state concentration achieved after 4-5 days of dosing.
In conclusion, O-Methyl Mycophenolic Acid is a useful alternative to Mycophenolic Acid for immunosuppressive therapy, with a similar mechanism of action and pharmacokinetics. Its chemical structure modification allows for improved bioavailability and reduced gastrointestinal side effects.
